Published in Prostate on May 01, 2001
Methylation of the RARB gene increases prostate cancer risk in black Americans. J Urol (2013) 0.86
Fluorescence time-resolved imaging system embedded in an ultrasound prostate probe. Biomed Opt Express (2010) 0.86
Contrast specific imaging in the detection and localization of prostate cancer. World J Urol (2004) 0.85
Value of enhanced transrectal ultrasound targeted biopsy for prostate cancer diagnosis: a retrospective data analysis. World J Urol (2011) 0.84
The Role of TURP in the Detection of Prostate Cancer in BPH Patients with Previously Negative Prostate Biopsy. Korean J Urol (2010) 0.84
Pathological correlation between needle biopsy and radical prostatectomy specimen in patients with localized prostate cancer. Can Urol Assoc J (2007) 0.81
Differences in Postoperative Pathological Outcomes between Prostate Cancers Diagnosed at Initial and Repeat Biopsy. Korean J Urol (2012) 0.81
Incremental value of transition zone and midline apical biopsy at baseline TRUS-guided biopsy for prostate cancer detection. World J Urol (2013) 0.78
A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients. Biomark Res (2014) 0.78
Clinicopathologic differences between prostate cancers detected during initial and repeat transrectal ultrasound-guided biopsy in Korea. Korean J Urol (2014) 0.75
Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis. Int J Mol Sci (2017) 0.75
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol (2001) 2.87
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol (2001) 2.83
Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol (2002) 2.34
Computerized analysis of smooth muscle fibers in potent and impotent patients. J Urol (1991) 2.13
Heat versus drugs in the treatment of benign prostatic hyperplasia. BJU Int (2003) 2.05
Revised analysis of aadA2 gene of plasmid pSa. Antimicrob Agents Chemother (1994) 2.03
Percutaneous stone manipulation. J Urol (1981) 2.00
Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ (2008) 1.99
Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol (2000) 1.94
Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. Eur Urol (2002) 1.91
Osteochondromyxoma of bone: a congenital tumor associated with lentigines and other unusual disorders. Am J Surg Pathol (2001) 1.90
Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract (2007) 1.88
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol (1999) 1.86
Turner phenotype with pelvic kidney and other unusual abnormalities. JAMA (1970) 1.80
Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol (1998) 1.73
Is transurethral resection of the prostate still justified? BJU Int (1999) 1.69
Radical prostatectomy for prostate cancer: the perineal approach increases the risk of surgically induced positive margins and capsular incisions. J Urol (1998) 1.66
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol (2010) 1.65
Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res (1995) 1.65
A multicenter, double-blind, randomized, parallel group study comparing polyvinyl chloride and polyvinyl chloride-free catheter materials. J Urol (2009) 1.63
Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study. J Urol (1997) 1.60
High-grade prostate cancer is associated with low serum testosterone levels. Prostate (2001) 1.59
Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest (1992) 1.57
Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren's syndrome. Arthritis Rheum (1999) 1.56
Transcription of a zein gene introduced into sunflower using a Ti plasmid vector. EMBO J (1984) 1.54
Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol (1995) 1.54
Male andropause: myth, reality, and treatment. Int J Impot Res (2002) 1.53
Morbidity of the evaluation of the lower urinary tract with transurethral multichannel pressure-flow studies. J Urol (1998) 1.51
Assessment of endpoints for clinical trials for localized prostate cancer. Urology (1997) 1.45
Impact of unfunded research in medicine, pathology, and surgery. South Med J (1995) 1.45
Handling and reporting of biopsy and surgical specimens of testicular cancer. Eur Urol (2004) 1.45
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res (1997) 1.44
[Intolerance to cow milk protein hydrolysates with digestive manifestations]. Arch Fr Pediatr (1993) 1.42
Ileocecal valve reconstruction during continent urinary diversion. J Urol (1994) 1.41
Congenital uro-nephropathies: is routine voiding cystourethrography always warranted? Clin Radiol (1998) 1.39
Effects of nimodipine on regional blood flow in heart and brain during cardiopulmonary resuscitation in pigs. Anesth Analg (1994) 1.39
The clinical implications of the prostate cancer prevention trial. BJU Int (2003) 1.38
Diagnostic accuracy of DNA image cytometry and urinary cytology with cells from voided urine in the detection of bladder cancer. Urology (2000) 1.38
Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol (1999) 1.36
Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res (2001) 1.35
Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. Eur Urol (1982) 1.35
Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol (1997) 1.34
p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res (1993) 1.34
A beta 1-integrin receptor for fibronectin in human kidney glomeruli. Am J Pathol (1989) 1.34
bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology (1998) 1.29
Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol (1994) 1.26
Cloning and sequencing of Mal d 1, the major allergen from apple (Malus domestica), and its immunological relationship to Bet v 1, the major birch pollen allergen. Biochem Biophys Res Commun (1995) 1.25
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet (2006) 1.24
Fetal uropathies: diagnostic pitfalls and management. J Urol (1985) 1.24
Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol (1998) 1.21
Urodynamic assessment of patients with acute urinary retention: is treatment failure after prostatectomy predictable? J Urol (1997) 1.21
Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy. J Immunol (1989) 1.21
Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest (1995) 1.20
Pseudoneoplastic lesions of the testis and paratesticular structures. Virchows Arch (2007) 1.19
Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Urology (1999) 1.18
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol (1999) 1.16
Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol (2000) 1.15
Venous leakage: surgical treatment of a curable cause of impotence. J Urol (1985) 1.14
Morphology of tissue destruction induced by focused ultrasound. Eur Urol (1993) 1.13
Pathological changes in prostate lesions after androgen manipulation. J Clin Pathol (1998) 1.13
Urolithiasis in allograft kidneys. Urology (2002) 1.13
The aging lower urinary tract: a comparative urodynamic study of men and women. Urology (1998) 1.13
Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol (1999) 1.13
Occupational risks of bladder cancer in France: a multicentre case-control study. Int J Epidemiol (1993) 1.12
Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Int J Cancer (1996) 1.12
Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol (2001) 1.11
Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol (1983) 1.11
Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis--a prospective randomized study. Br J Urol (1994) 1.11
Incidence of testicular microlithiasis. Urology (1992) 1.11
Tobacco and bladder cancer in males: increased risk for inhalers and smokers of black tobacco. Int J Cancer (1989) 1.10
Extraperitoneal laparoscopic radical prostatectomy. Results after 50 cases. Eur Urol (2001) 1.10
Pathogenic antibodies inhibit the binding of apolipoproteins to megalin/gp330 in passive Heymann nephritis. J Clin Invest (1997) 1.10
High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol (1995) 1.10
Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol (2005) 1.10
Endoscopic injections of Teflon to treat urinary incontinence in women. Br Med J (Clin Res Ed) (1984) 1.10
Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol (1997) 1.09
Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. J Urol (1998) 1.09
Insulin-like growth factors and prostate cancer. World J Urol (2001) 1.09
Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst (1989) 1.08